Pharmacy Intervention Matters: Improving the Quality of Care of Helicobacter pylori Treatment
Authors:
- Omar SoudanOSOmar Soudan
- Rand SoudanRSRand Soudan
- Tara KoehlerTKTara Koehler
- Nimisha VasandaniNVNimisha Vasandani
- Apryl CronleyACApryl Cronley
- Pooja J. MudePMPooja J. Mude
- Ahmad AlkaddourAAAhmad Alkaddour
- Carlos PalacioCPCarlos Palacio
- John Erikson L. YapJYJohn Erikson L. Yap
- Kenneth J. VegaKVKenneth J. Vega
Open Access
- 1 November 2026
- journal article
- research article
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (4) , 71
Abstract
Objectives: Helicobacter pylori (HP) infection has an estimated prevalence of ~4.4 billion individuals worldwide. Clinical manifestations range from asymptomatic to mucosa-associated lymphoid tissue lymphoma. Effective eradication depends on both appropriate treatment selection and patient adherence. The study aims were compare HP eradication rates, antibiotic regimen selection and confirmation testing between patients managed by a clinical pharmacist versus standard care. Methods: A retrospective review of adults diagnosed and treated for HP was performed between March 2019 and November 2021. Patients were divided into two sequential cohorts: a pre-pharmacy group receiving standard care, and a pharmacist intervention group in which a clinical pharmacist managed treatment and documented HP eradication. Data analyzed included multiple demographic and clinical factors. Eradication was assessed by intention-to-treat (ITT) and per-protocol analysis with proportions compared using chi-square or Fisher’s Exact Test for low cell counts. Results: A total of 134 patients were diagnosed and treated for HP during the study period: 38 in the pre-pharmacy group and 96 in the pharmacist intervention group. In ITT analysis, successful eradication did not differ significantly between groups. Per-protocol analysis revealed significantly higher eradication in the pharmacist group. Antibiotic regimens overall differed between the cohorts with less use of clarithromycin-based triple therapy and greater use of non-bismuth quadruple (concomitant) therapy in the pharmacist group. Other evaluated items were not significantly different between groups. Conclusions: Clinical pharmacist HP care management was associated with more consistent, guideline-concordant antibiotic regimen selection and higher eradication rates among patients completing confirmatory testing. These findings support a role for pharmacist-led HP care for process improvement including regimen selection and eradication testing; prospective studies with systematic confirmatory testing are needed to determine the model’s effect on eradication itself.Keywords
This publication has 11 references indexed in Scilit:
- Artificial intelligence in optimizing antimicrobial therapy for gastro-renal disordersFrontiers in Cellular and Infection Microbiology, 2026
- ACG Clinical Guideline: Treatment of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2024
- EFFECT OF PHARMACIST COUNSELING ON PATIENT MEDICATION COMPLIANCE AND HELICOBACTER PYLORI ERADICATION AMONG JORDANIAN OUTPATIENTSArquivos de Gastroenterologia, 2023
- Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus reportGut, 2022
- Pharmacist-Managed Helicobacter pylori Treatment Service Within a Gastroenterology Clinic: Workflow and Real-World ExperiencesAnnals of Pharmacotherapy, 2021
- Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-AnalysisGastroenterology, 2017
- ACG Clinical Guideline: Treatment of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2017
- Review: Improving compliance with Helicobacter pylori eradication therapy: when and how?Therapeutic Advances in Gastroenterology, 2009
- H pylori antibiotic resistance: prevalence, importance, and advances in testingGut, 2004
- A Randomized Controlled Trial of an Enhanced Patient Compliance Program for Helicobacter pylori TherapyArchives of internal medicine (1960), 1999